← Back to Treatments
🏅 FDA Orphan Designation

AQNEURSA

LEVACETYLLEUCINE

Manufacturer: IntraBio Inc

Indicated for:
Niemann-Pick disease type C

FDA-Approved Indications (1)

indicated for the treatment of neurological manifestations of Niemann-Pick disease type C (NPC) in adults and pediatric patients weighing ≥15 kg

Population: adults and pediatric patients weighing ≥15 kg

Indications & Usage

1 INDICATIONS AND USAGE AQNEURSA™ is indicated for the treatment of neurological manifestations of Niemann-Pick disease type C (NPC) in adults and pediatric patients weighing ≥15 kg. AQNEURSA is indicated for the treatment of neurological manifestations of Niemann-Pick disease type C (NPC) in adults and pediatric patients weighing ≥15 kg. ( 1 )

💙 Support Programs

View all →
AQNEURSA
IntraBio Inc

Where shown, WAC (Wholesale Acquisition Cost) is an estimate only — your actual cost depends on your insurance plan. Always verify pricing with your pharmacy or insurer.

Medical disclaimer: This information is for educational purposes only. Always consult a qualified healthcare provider before making treatment decisions. Data sourced from FDA and current as of our last update.